Host phenotype is associated with reduced survival independent of tumour biology in patients with colorectal liver metastases.
Aged
Body Composition
Colorectal Neoplasms
/ diagnostic imaging
Female
Humans
Inflammation
/ diagnostic imaging
Intra-Abdominal Fat
/ diagnostic imaging
Liver Neoplasms
/ diagnostic imaging
Male
Middle Aged
Muscle, Skeletal
/ diagnostic imaging
Phenotype
Prognosis
Subcutaneous Fat
/ diagnostic imaging
Survival Analysis
Tomography, X-Ray Computed
Colorectal cancer
Inflammation
Liver metastases
Sarcopenia
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
16
05
2018
revised:
24
08
2018
accepted:
13
09
2018
pubmed:
1
11
2018
medline:
9
4
2020
entrez:
1
11
2018
Statut:
ppublish
Résumé
Most prognostic scoring systems for colorectal liver metastases (CRLMs) account for factors related to tumour biology. Little is known about the effects of the host phenotype to the tumour. Our objective was to delineate the relationship of systemic inflammation and body composition features [i.e. low skeletal muscle mass (sarcopenia) and low visceral adipose tissue (VAT)], two well-described host phenotypes in cancer. Clinical data and pre-operative blood samples were collected from 99 patients who underwent resection of CRLM. Pre-operative computed tomography scans were available for 97 patients; body composition was analysed at the L3 level, stratified for sex and age. Clinicopathological variables, serum C-reactive protein (CRP), and various body composition variables were evaluated. Overall survival was evaluated as a function of these same variables in multivariate Cox regression analysis. Skeletal muscle was significantly correlated with VAT (r = 0.46, P < 0.001). Of patients with sarcopenia, 35 (65%) also had low VAT. C-reactive protein was elevated (≥5 mg/mL) in 42 patients (43.3%). Elevated CRP was more common in patients with sarcopenia (73.8% vs. 51.1%, P = 0.029). The most significant prognostic factors were the coincidence of elevated CRP and adverse body composition features (sarcopenia and/or low VAT; hazard ratio 4.3, 95% confidence interval 1.5-13.0, P = 0.008), as well as Fong clinical prognostic score (hazard ratio 2.9, 95% confidence interval 1.5-5.5, P = 0.002). Body composition in patients with CRLM is not directly linked to the presence of systemic inflammation. However, when systemic inflammation coincides with sarcopenia and/or low VAT, prognosis is adversely affected, independent of the Fong clinical prognostic score.
Sections du résumé
BACKGROUND
Most prognostic scoring systems for colorectal liver metastases (CRLMs) account for factors related to tumour biology. Little is known about the effects of the host phenotype to the tumour. Our objective was to delineate the relationship of systemic inflammation and body composition features [i.e. low skeletal muscle mass (sarcopenia) and low visceral adipose tissue (VAT)], two well-described host phenotypes in cancer.
METHODS
Clinical data and pre-operative blood samples were collected from 99 patients who underwent resection of CRLM. Pre-operative computed tomography scans were available for 97 patients; body composition was analysed at the L3 level, stratified for sex and age. Clinicopathological variables, serum C-reactive protein (CRP), and various body composition variables were evaluated. Overall survival was evaluated as a function of these same variables in multivariate Cox regression analysis.
RESULTS
Skeletal muscle was significantly correlated with VAT (r = 0.46, P < 0.001). Of patients with sarcopenia, 35 (65%) also had low VAT. C-reactive protein was elevated (≥5 mg/mL) in 42 patients (43.3%). Elevated CRP was more common in patients with sarcopenia (73.8% vs. 51.1%, P = 0.029). The most significant prognostic factors were the coincidence of elevated CRP and adverse body composition features (sarcopenia and/or low VAT; hazard ratio 4.3, 95% confidence interval 1.5-13.0, P = 0.008), as well as Fong clinical prognostic score (hazard ratio 2.9, 95% confidence interval 1.5-5.5, P = 0.002).
CONCLUSIONS
Body composition in patients with CRLM is not directly linked to the presence of systemic inflammation. However, when systemic inflammation coincides with sarcopenia and/or low VAT, prognosis is adversely affected, independent of the Fong clinical prognostic score.
Identifiants
pubmed: 30378742
doi: 10.1002/jcsm.12358
pmc: PMC6438330
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
123-130Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2018 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders.
Références
Biochem Biophys Res Commun. 2004 May 21;318(1):168-75
pubmed: 15110769
J Hepatol. 2015 Jul;63(1):131-40
pubmed: 25724366
Ann Surg. 2009 Sep;250(3):440-8
pubmed: 19730175
J Cachexia Sarcopenia Muscle. 2015 Sep;6(3):212-21
pubmed: 26401467
PLoS One. 2012;7(4):e34318
pubmed: 22496788
HPB (Oxford). 2011 Jul;13(7):439-46
pubmed: 21689226
HPB (Oxford). 2015 May;17(5):438-46
pubmed: 25512239
J Gastric Cancer. 2017 Mar;17(1):74-87
pubmed: 28337365
Cancer Res. 2014 Jan 1;74(1):330-40
pubmed: 24197136
Br J Surg. 2016 Apr;103(5):572-80
pubmed: 26994716
Eur J Cancer. 2013 Feb;49(3):741-51
pubmed: 23040637
Eur J Cancer. 2010 Mar;46(4):791-9
pubmed: 20018503
Ann Surg. 1994 Apr;219(4):325-31
pubmed: 7512810
Ann Surg Oncol. 2009 Jul;16(7):1809-19
pubmed: 18979139
J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):123-130
pubmed: 30378742
HPB (Oxford). 2010 May;12(4):227-38
pubmed: 20590892
Diabetes. 2002 May;51(5):1319-36
pubmed: 11978627
PLoS One. 2014 Jul 17;9(7):e101717
pubmed: 25032825
Science. 2000 Sep 29;289(5488):2363-6
pubmed: 11009425
J Surg Oncol. 2016 Dec;114(7):895-899
pubmed: 27696432
BMC Cancer. 2014 Jul 28;14:542
pubmed: 25069793
Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006
pubmed: 18923576
J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):317-326
pubmed: 27897432
Clin Nutr. 2018 Aug;37(4):1279-1285
pubmed: 28566220
Br J Cancer. 2007 Jan 29;96(2):222-5
pubmed: 17211465
Cell Metab. 2012 Aug 8;16(2):153-66
pubmed: 22795476
Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21
pubmed: 10493478
J Cachexia Sarcopenia Muscle. 2017 Dec;8(6):1081-1083
pubmed: 29098794
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Br J Surg. 2012 Apr;99(4):550-7
pubmed: 22246799
Br J Surg. 2010 Jul;97(7):1110-8
pubmed: 20632280
Ann Surg. 2016 Feb;263(2):320-5
pubmed: 25643288
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
Ann Surg. 2008 Jan;247(1):125-35
pubmed: 18156932
Ann Surg Oncol. 2014 May;21(5):1711-8
pubmed: 24452408
Am J Pathol. 2005 Sep;167(3):749-59
pubmed: 16127154
Int J Surg. 2016 Dec;36(Pt A):8-12
pubmed: 27742565
FASEB J. 2005 Mar;19(3):362-70
pubmed: 15746179
J Clin Invest. 2011 Jun;121(6):2111-7
pubmed: 21633179
BMC Cancer. 2010 Sep 16;10:496
pubmed: 20846416